- Home
- MMT vs AVIR Comparison
MMT vs AVIR Comparison
Compare MMT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMT
- AVIR
- Stock Information
- Founded
- MMT 1987
- AVIR 2012
- Country
- MMT United States
- AVIR United States
- Employees
- MMT N/A
- AVIR N/A
- Industry
- MMT Trusts Except Educational Religious and Charitable
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- MMT Finance
- AVIR Health Care
- Exchange
- MMT Nasdaq
- AVIR Nasdaq
- Market Cap
- MMT 270.5M
- AVIR 290.4M
- IPO Year
- MMT N/A
- AVIR 2020
- Fundamental
- Price
- MMT $4.80
- AVIR $3.56
- Analyst Decision
- MMT
- AVIR Hold
- Analyst Count
- MMT 0
- AVIR 1
- Target Price
- MMT N/A
- AVIR $6.88
- AVG Volume (30 Days)
- MMT 86.5K
- AVIR 152.3K
- Earning Date
- MMT 01-01-0001
- AVIR 11-06-2024
- Dividend Yield
- MMT 8.58%
- AVIR N/A
- EPS Growth
- MMT N/A
- AVIR N/A
- EPS
- MMT 0.30
- AVIR N/A
- Revenue
- MMT N/A
- AVIR N/A
- Revenue This Year
- MMT N/A
- AVIR N/A
- Revenue Next Year
- MMT N/A
- AVIR N/A
- P/E Ratio
- MMT $15.33
- AVIR N/A
- Revenue Growth
- MMT N/A
- AVIR N/A
- 52 Week Low
- MMT $4.04
- AVIR $2.77
- 52 Week High
- MMT $4.70
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- MMT 37.80
- AVIR 49.38
- Support Level
- MMT $4.84
- AVIR $3.31
- Resistance Level
- MMT $4.89
- AVIR $3.86
- Average True Range (ATR)
- MMT 0.03
- AVIR 0.12
- MACD
- MMT -0.01
- AVIR 0.03
- Stochastic Oscillator
- MMT 0.00
- AVIR 46.90
About MMT MFS Multimarket Income Trust
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, airlines, automotive, chemicals, electronics, and others.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).